Top Markets
#1 Wibx Wibx +8.04%
#2 Wrapped Flare Wrapped Flare +4.46%
#3 Decred Decred +4.31%
#4 Humanity Humanity +4.26%
#5 Across Protocol Across Protocol +3.82%
#6 Pearl Pearl +3.51%
#7 aelf aelf +3.44%
#8 Audiera Audiera +2.66%
#9 MarsCoin MarsCoin +2.24%
#10 TRIA TRIA +2.06%
Coin of the day
Wibx Wibx
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Clovis Oncology, Inc. Clovis Oncology, Inc.

Clovis Oncology, Inc.

C6O
Classifica tra le azioni #30761
Clovis Oncology, Inc. is a biopharmaceutical company focused on the discovery,... Clovis Oncology, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of anti-cancer agents, serving markets in the United States, Europe, and globally. Its flagship commercial product in the U.S. is Rubraca (rucaparib), an oral small molecule designed to inhibit poly ADP-ribose polymerase. This treatment is indicated for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, Rubraca is offered for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. The company's pipeline includes lucitanib, an investigational angiogenesis inhibitor that targets vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/ß), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3). Also under development is FAP-2286, an investigational peptide-targeted radionuclide therapy and imaging agent that specifically acts upon fibroblast activation protein. Rubraca is distributed through a select network of specialty distributors and pharmacies, which then supply the medication to patients and healthcare providers. Clovis Oncology has established strategic collaborations, including license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and 3B Pharmaceuticals GmbH. The company also maintains a clinical collaboration with Bristol Myers Squibb Company and a partnership with Foundation Medicine, Inc. Founded in 2009, Clovis Oncology, Inc. is headquartered in Boulder, Colorado.
Prezzo delle azioni
$0.10794012
Ultima sincronizzazione: 2022-12-15
Capitalizzazione di mercato
$15.65M
Variazione (1 giorno)
-17.06%
Variazione (1 anno)
0.00%
Paese
US
Scambia Clovis Oncology, Inc. (C6O)

Categoria

Healthcare
Il prezzo C6O con la capitalizzazione del mercato della B
Clovis Oncology, Inc. Clovis Oncology, Inc.
C6O
$0.10794012
Capitalizzazione di mercato di Clovis Oncology, Inc.(C6O)
Capitalizzazione di mercato: $15.65M
A partire dal August 2026, Clovis Oncology, Inc. ha una capitalizzazione di mercato pari a $15.65M. Questo rende Clovis Oncology, Inc. la 30761st azienda più preziosa al mondo per capitalizzazione di mercato secondo i nostri dati. La capitalizzazione di mercato è il valore totale delle azioni in circolazione di una società quotata e viene comunemente utilizzata per misurarne il valore.
Storia della capitalizzazione di mercato di Clovis Oncology, Inc. dal 2019 al 2026
C6O in paragone con la classifica dei più popolari stocks
Il prezzo per C6O Attivo B Capitalizzazione del mercato a B Risultati
Clovis Oncology, Inc. Clovis Oncology, Inc.
$36,608.46 $15.65M
NVIDIA Corporation NVIDIA Corporation
NVDA
$5.307T +33,915,422.95%
Clovis Oncology, Inc. Clovis Oncology, Inc.
$31,394.09 $15.65M
Apple Inc. Apple Inc.
AAPL
$4.551T +29,084,627.94%
Clovis Oncology, Inc. Clovis Oncology, Inc.
$28,659.67 $15.65M
Alphabet Inc. Alphabet Inc.
GOOG
$4.154T +26,551,350.44%
Clovis Oncology, Inc. Clovis Oncology, Inc.
$24,756.27 $15.65M
Microsoft Corporation Microsoft Corporation
MSFT
$3.589T +22,935,091.10%
Clovis Oncology, Inc. Clovis Oncology, Inc.
$19,294.58 $15.65M
Amazon.com, Inc. Amazon.com, Inc.
AMZN
$2.797T +17,875,163.56%